A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Rivals include Johnson & Johnson's pharma unit Janssen which bought rights to a gene therapy for the condition from Hemera Biosciences, as well as Novartis which acquired a GA project as part of ...